ERBB2 and breast carcinoma: At the 2022 San Antonio Breast Cancer Symposium (SABCS), Turner presented the results from the CAPItello-291 phase III trial, showing a statistically significant and clinically meaningful improvement in PFS with the combination of fulvestrant and capivasertib in patients with HER2+/HER2-low or negative MBC, following recurrence or progression on, or after, endocrine therapy (with or without a CDK4/6 inhibitor) [94].